Abstract
Obesity is a chronic disease characterized by the accumulation of excess adipose tissue associated with an increased risk of multiple morbidities and mortality. At the present time, only three drugs have been approved by the Food and Drug Administration (FDA) for the treatment of obesity. Agonists and antagonists of some of the substances implicated in the regulation of energy homeostasis represent opportunities for anti-obesity drug development. The most promising targets are alpha-melanocyte stimulating hormone (alpha- MSH) receptors, cannabinoid receptors, the 5-hydroxytryptamine (5-HT) receptors and melanin-concentrating hormone (MCH) receptors. MCH receptors could be major potential targets for the treatment of obesity. Many pharmaceutical companies have described MCH-R1 antagonists that have appeared over the past year. Recently, two compounds went into phase I clinical trials that evaluate MCH receptor antagonists as a new perspective for the pharmacologic treatment of obesity. In this review, structure-activity relationships (SAR) in the development of MCH-R1 antagonists are provided.
Keywords: Antagonists, melanin-concentrating hormone (MCH), melanin-concentrating hormone receptor 1 (MCH-R1), structure-activity relationship (SAR), obesity
Current Medicinal Chemistry
Title: Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Volume: 15 Issue: 10
Author(s): Gildardo Rivera, Virgilio Bocanegra-Garcia, Silvia Galiano, Nuria Cirauqui, Javier Ceras, Silvia Perez, Ignacio Aldana and Antonio Monge
Affiliation:
- Departamento de Farmacia y Quimica Medicinal, Universidad Autonoma de Tamaulipas, Calle 16 y Lago de Chapala, s/n,88740, Reynosa, Mexico.,Mexico
Keywords: Antagonists, melanin-concentrating hormone (MCH), melanin-concentrating hormone receptor 1 (MCH-R1), structure-activity relationship (SAR), obesity
Abstract: Obesity is a chronic disease characterized by the accumulation of excess adipose tissue associated with an increased risk of multiple morbidities and mortality. At the present time, only three drugs have been approved by the Food and Drug Administration (FDA) for the treatment of obesity. Agonists and antagonists of some of the substances implicated in the regulation of energy homeostasis represent opportunities for anti-obesity drug development. The most promising targets are alpha-melanocyte stimulating hormone (alpha- MSH) receptors, cannabinoid receptors, the 5-hydroxytryptamine (5-HT) receptors and melanin-concentrating hormone (MCH) receptors. MCH receptors could be major potential targets for the treatment of obesity. Many pharmaceutical companies have described MCH-R1 antagonists that have appeared over the past year. Recently, two compounds went into phase I clinical trials that evaluate MCH receptor antagonists as a new perspective for the pharmacologic treatment of obesity. In this review, structure-activity relationships (SAR) in the development of MCH-R1 antagonists are provided.
Export Options
About this article
Cite this article as:
Rivera Gildardo, Bocanegra-Garcia Virgilio, Galiano Silvia, Cirauqui Nuria, Ceras Javier, Perez Silvia, Aldana Ignacio and Monge Antonio, Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity, Current Medicinal Chemistry 2008; 15(10) . https://dx.doi.org/10.2174/092986708784049621
DOI https://dx.doi.org/10.2174/092986708784049621 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Diabetes and Vascular Disease: Is It All About Glycemia?
Current Pharmaceutical Design Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design Subject Index To Volume 13
Current Medicinal Chemistry Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Can Group Exercise Programs Improve Health Outcomes in Pregnant Women? A Systematic Review
Current Women`s Health Reviews Review of Patents on Microneedle Applicators
Recent Patents on Drug Delivery & Formulation Buccoadhesive Dosage Form Containing Antifungal Agent for Treating Oropharyngeal Candidiasis: A Review
Current Drug Therapy Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design
Current Alzheimer Research Complex Obesity
Current Pediatric Reviews Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.
Current Vascular Pharmacology Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Editorial [Hot Topic: New Insight in Obesity and Insulin Resistance (Guest Editor: Geltrude Mingrone)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Endothelin Receptor Antagonists as Disease Modifiers in Systemic Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Meet the Editorial Board:
Medicinal Chemistry Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents Neuronal Regulators and Vascular Dysfunction in Raynauds Phenomenon and Systemic Sclerosis
Current Vascular Pharmacology Alzheimers Disease, Ceramide, Visfatin and NAD
CNS & Neurological Disorders - Drug Targets Nesfatin/Nucleobindin-2 (NUCB2) and Glucose Homeostasis
Current Hypertension Reviews Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design